Asenapine: a new approach in the treatment of bipolar disorder

被引：0

作者：

Di Sciascio, G. ^{[1
]}

Calo, S. ^{[2
]}

机构：

[1] Azienda Osped Univ Consorziale Polclin Bari, Unita Operat Psichiat Univ, Bari, Italy

[2] ASL Brindisi, Serv Psichiat Diag & Cura, Brindisi, Italy

来源：

JOURNAL OF PSYCHOPATHOLOGY-GIORNALE DI PSICOPATOLOGIA | 2012年 / 18卷 / 01期

关键词：

Bipolar disorder; Antipsychotics; Asenapine;

D O I：

暂无

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Asenapine is a second-generation antipsychotic that is administered sublingually; the compound received regulatory approval two years ago by FDA for the acute treatment of schizophrenia in adults, and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. In the EMA, at the present, asenapine is approved only for the acute treatment of manic episodes associated with bipolar I disorder in adults. The aim of this review is to summarize published data in both the literature and regulatory documents on efficacy and safety of asenapine for the treatment of bipolar disorder.

引用

页码：92 / 102

页数：11

共 43 条

[1]

American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596

[2] Central 5-HT2A and D-2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men [J].

Andree, B ;

Halldin, C ;

VrijmoeddeVries, M ;

Farde, L .

PSYCHOPHARMACOLOGY, 1997, 131 (04) :339-345

[3]

Bishara D, 2009, NEUROPSYCH DIS TREAT, V5, P483

[4]

Calabrese J, 2010, EUR PSYCHIAT, V25, P1447

[5] Asenapine A Review of its Use in the Management of Mania in Adults with Bipolar I Disorder [J].

Chwieduk, Claudine M. ;

Scott, Lesley J. .

CNS DRUGS, 2011, 25 (03) :251-267

[6] Dose selection of asenapine: application of models based on D2 occupancy to predict efficacy and safety [J].

de Greef, R. ;

Maloney, A. ;

Olsson-Gisleskog, P. ;

Prins, K. ;

Schoemaker, J. ;

Panagides, J. .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 :S436-S436

[7] Asenapine pharmacokinetics: influence of cytochrome p450 modulators and udp-glucuronyltransferase inhibition [J].

Dogterom, P. ;

Hulskotte, E. ;

Gerrits, M. ;

Timmer, C. ;

Sitsen, J. M. Ad ;

de Greef, H. ;

Spaans, E. ;

Peeters, P. .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 :S452-S453

[8]

Dogterom P, 2008, CLIN PHARMACOL THER, V83, pS55

[9] Asenapine, a novel psychopharmacologic agent:: preclinical evidence for clinical effects in schizophrenia [J].

Franberg, Olivia ;

Wiker, Charlotte ;

Marcus, Monica M. ;

Konradsson, Asa ;

Jardemark, Kent ;

Schilstrom, Bjorn ;

Shahid, Mohammed ;

Wong, Erik H. F. ;

Svensson, Torgny H. .

PSYCHOPHARMACOLOGY, 2008, 196 (03) :417-429

[10] Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms [J].

Franberg, Olivia ;

Marcus, Monica M. ;

Ivanov, Vladimir ;

Schilstrom, Bjorn ;

Shahid, Mohammed ;

Svensson, Torgny H. .

PSYCHOPHARMACOLOGY, 2009, 204 (02) :251-264

← 1 2 3 4 5 →